DENVER — A large phase 2b study showed that the use of Aerie Pharmaceuticals’ AR-15512 compound resulted in improved tear production and dry eye symptoms at 7 days and 14 days, according to David Wirta, MD, of the Eye Research Foundation. The TRPM8 cold thermoreceptor agonist affects the receptors on the conjunctiva, cornea and eyelid to stimulate a cold feeling to the eye, leading to reflex tearing, Wirta said.
VIDEO: Dry eye treatment improves signs, symptoms at 1 week
DENVER — A large phase 2b study showed that the use of Aerie Pharmaceuticals’ AR-15512 compound resulted in improved tear production and dry eye symptoms at 7 days and 14 days, according to David Wirta, MD, of the Eye Research Foundation. The TRPM8 cold thermoreceptor agonist affects the receptors on the conjunctiva, cornea and eyelid to stimulate a cold feeling to the eye, leading to reflex tearing, Wirta said.